Skip to content

Clinical trials

Phase 1 Uterine Cervical Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Uterine Cervical Neoplasms Phase: Phase 1 Country / region: United States Clear all

167 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20015
20021
20034
20043
20058
20064
20074
20082
20092
20105
20114
20123
20133
20142
20157
20163
20171
201812
201913
202013
202115
20228
20239
202410
202511
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed85
Terminated29
Recruiting21
Active, not recruiting20
Unknown status6
Withdrawn4
Suspended1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)17
M.D. Anderson Cancer Center8
Gynecologic Oncology Group5
Eli Lilly and Company4
AstraZeneca3
Incyte Corporation3
MacroGenics3
Masonic Cancer Center, University of Minnesota3
Seagen Inc.3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Uterine Cervical Neoplasms167
Endometrial Neoplasms63
Ovarian Neoplasms62
Carcinoma, Non-Small-Cell Lung60
Stomach Neoplasms47
Squamous Cell Carcinoma of Head and Neck43
Breast Neoplasms42
Melanoma40
Carcinoma, Renal Cell39
Esophageal Neoplasms37

Trials

Showing 1 to 25 of 167. Each trial links to its page on Pharma Observatory.

67 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.